These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12534799)

  • 1. Expression of syndecan-1 is a sensitive marker for cutaneous plasmacytoma.
    Bayer-Garner IB; Joseph L; Sanderson RD; Smoller BR
    J Cutan Pathol; 2003 Jan; 30(1):18-22. PubMed ID: 12534799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD117, but not lysozyme, is positive in cutaneous plasmacytoma.
    Bayer-Garner IB; Schwartz MR; Lin P; Smoller BR
    Arch Pathol Lab Med; 2003 Dec; 127(12):1596-8. PubMed ID: 14632572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitary plasmacytoma of the skull: immunohistochemical study of angiogenic factors and syndecan-1--two case reports.
    Naganuma H; Sakatsume S; Sugita M; Satoh E; Asahara T; Nukui H
    Neurol Med Chir (Tokyo); 2004 Apr; 44(4):195-200. PubMed ID: 15185759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Syndecan-1 (CD138): an immunohistochemical marker of plasma cell tumors].
    Fakan F; Boudová L; Hejda C
    Cesk Patol; 2002 Jan; 38(1):33-6. PubMed ID: 11933459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
    Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
    Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic cutaneous plasmacytoma: a case report associated with IgA lambda multiple myeloma and a review of the literature of metastatic cutaneous plasmacytomas associated with multiple myeloma and primary cutaneous plasmacytomas.
    Kato N; Kimura K; Yasukawa K; Aikawa K
    J Dermatol; 1999 Sep; 26(9):587-94. PubMed ID: 10535253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
    Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
    Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
    Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
    Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The expression, secretion and regulation of membrane-soluble syndecan-1 in human multiple myeloma cells].
    Li X; Lu Z; Klein B
    Zhonghua Xue Ye Xue Za Zhi; 2000 Nov; 21(11):572-6. PubMed ID: 11225246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecans and the lymphoid system.
    Kopper L; Sebestyén A
    Leuk Lymphoma; 2000 Jul; 38(3-4):271-81. PubMed ID: 10830734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary extramedullary plasmacytoma of the small intestine. A case report and review of the literature.
    Moriyama H; Kawahara K; Noguchi T; Kikuchi R; Wada S; Takeno S; Kashima K
    J Exp Clin Cancer Res; 2006 Mar; 25(1):129-34. PubMed ID: 16761629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Solitary plasmacytoma of bone: a clinicopathologic, immunohistochemical and immunoglobulin gene rearrangement study].
    Zuo Z; Liu WP; Tang Y; Bi CF; Wang XQ; Zhang WY; Yang QP; Zou LQ
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):177-82. PubMed ID: 20450765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of primary cutaneous plasmacytoma-like lymphoproliferative disorder following renal transplantation.
    Molina-Ruiz AM; Pulpillo A; Lasanta B; Zulueta T; Andrades R; Requena L
    J Cutan Pathol; 2012 Jul; 39(7):685-9. PubMed ID: 22574640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma.
    Bayer-Garner IB; Dilday B; Sanderson RD; Smoller BR
    Am J Dermatopathol; 2000 Apr; 22(2):119-22. PubMed ID: 10770430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Secondary cutaneous plasmacytoma revealing multiple myeloma: about a case].
    Ngolet LO; N'soundhat NL; Ndounga E; Kocko I; Kidédé DC; Ntsiba H
    Pan Afr Med J; 2016; 24():44. PubMed ID: 27642385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
    Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
    Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous plasmacytomas in myeloma. Relationship to tumor cell burden.
    Alberts DS; Lynch P
    Arch Dermatol; 1978 Dec; 114(12):1784-7. PubMed ID: 736585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.